How I’m embracing the journey while living with both PF and aging

My granddaughters remind me why I pursued a lung transplant

“They’re here!” Much like the scenes in movies where grandparents see their grandchildren arriving, I shouted those words on Father’s Day to let my wife, Susan, know it was game time. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, there were things I hadn’t…

IPF treatment AGMB-447 granted FDA orphan drug status

AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 1 clinical trial, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to therapies that may improve care for people with rare diseases,…

Lixudebart for IPF receives orphan drug status from FDA

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to support the accelerated development of investigational treatments for rare diseases, defined as those affecting fewer than 200,000…

Study: ENV-101 improves IPF lung function, reverses fibrosis

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late-breaking oral…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums